Exact Sciences Corporation $EXAS Shares Bought by Chicago Partners Investment Group LLC

Chicago Partners Investment Group LLC grew its position in Exact Sciences Corporation (NASDAQ:EXAS) by 14.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,070 shares of the medical research company’s stock after purchasing an additional 1,429 shares during the quarter. Chicago Partners Investment Group LLC’s holdings in Exact Sciences were worth $536,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Exact Sciences in the 1st quarter valued at $34,000. Cerity Partners LLC raised its holdings in shares of Exact Sciences by 24.0% in the 1st quarter. Cerity Partners LLC now owns 33,598 shares of the medical research company’s stock valued at $1,454,000 after purchasing an additional 6,508 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Exact Sciences in the 1st quarter valued at $1,171,000. GAMMA Investing LLC raised its holdings in shares of Exact Sciences by 15.5% in the 1st quarter. GAMMA Investing LLC now owns 4,243 shares of the medical research company’s stock valued at $184,000 after purchasing an additional 569 shares in the last quarter. Finally, Woodline Partners LP raised its holdings in shares of Exact Sciences by 62.0% in the 1st quarter. Woodline Partners LP now owns 537,863 shares of the medical research company’s stock valued at $23,284,000 after purchasing an additional 205,875 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Exact Sciences

In other Exact Sciences news, Director James Edward Doyle sold 2,000 shares of the firm’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total transaction of $120,000.00. Following the transaction, the director directly owned 57,962 shares of the company’s stock, valued at approximately $3,477,720. This trade represents a 3.34% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 1.20% of the company’s stock.

Exact Sciences Trading Down 0.8%

Shares of Exact Sciences stock opened at $62.91 on Thursday. Exact Sciences Corporation has a 1 year low of $38.81 and a 1 year high of $72.83. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.56 and a current ratio of 2.89. The company has a market capitalization of $11.91 billion, a P/E ratio of -11.59, a PEG ratio of 5.62 and a beta of 1.24. The company’s fifty day moving average is $53.47 and its two-hundred day moving average is $51.47.

Exact Sciences (NASDAQ:EXAS) last issued its quarterly earnings data on Wednesday, August 6th. The medical research company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.24. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The company had revenue of $811.09 million for the quarter, compared to the consensus estimate of $774.43 million. During the same period last year, the firm posted ($0.09) EPS. Exact Sciences’s revenue for the quarter was up 16.0% on a year-over-year basis. Analysts forecast that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Craig Hallum raised their price objective on shares of Exact Sciences from $65.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, September 11th. Piper Sandler lifted their price target on shares of Exact Sciences from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 8th. Royal Bank Of Canada cut their price target on shares of Exact Sciences from $54.00 to $46.00 and set a “sector perform” rating on the stock in a research note on Thursday, August 7th. Cowen reiterated a “buy” rating on shares of Exact Sciences in a research note on Thursday, August 7th. Finally, BTIG Research lifted their price target on shares of Exact Sciences from $60.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $69.90.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.